Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET
Company Participants
Mary Jenkins – Associate Director, Investor Relations and Corporate Communications
Douglas Ingram – President and Chief Executive Officer
Dallan Murray – Executive Vice President and Chief Customer Officer
Louise Rodino-Klapac – Executive Vice President, Chief Scientific Officer and Head of Research & Development
Ian Estepan – Executive Vice President and Chief Financial Officer
Conference Call Participants
Tazeen Ahmad – Bank of America Merrill Lynch
Gena Wang – Barclays
Andrew Tsai – Jefferies
Anupam Rama – JPMorgan
Danielle Brill – Raymond James
Eliana Merle – UBS
Gil Blum – Needham & Company
Ritu Baral – TD Cowen
Joseph Schwartz – Leerink Partners
Kostas Biliouris – BMO Capital Markets
Brian Skorney – Baird
Kristen Kluska – Cantor Fitzgerald
Biren Amin – Piper Sandler
Gavin Clark-Gartner – Evercore ISI
Leo Watson – Mizuho
Sami Corwin – William Blair
Operator
Good day and welcome to the Sarepta Therapeutics Third Quarter 2024 Financial Results Conference Call. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today’s conference is being recorded.
At this time, I would now like to turn the call over Mary Jenkins, Associate Director, Investor Relations and Corporate Communications. Please go ahead.
Mary Jenkins
Thank you, Michelle, and thank you all for joining today’s call. Earlier this afternoon, we released our financial results for the third quarter 2024. The press release is available on our website at sarepta.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon.
Joining us on the call today are Doug Ingram; Ian Estepan; Dallan Murray; and Dr. Louise Rodino-Klapac. After our formal remarks, we’ll open the call for Q&A.
I’d like to note that, during this call, we will be making a number
Read the full article here
